FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 25, 2026, 10:56PMOS Can Affect Much More Than Periods or Fertility – PCOS Awareness Association
-
Jul 25, 2026, 10:42Asma Khalil: Recreational Drug Use During Pregnancy, What Every Expectant Mother Should Know!
-
Jul 25, 2026, 10:40Khalil Faaed: Are Complex Y Chromosome Rearrangements the Missing Link in Unexplained Male Infertility?
-
Jul 25, 2026, 10:38Sean Lauber: Does Transferring a Cleavage or Blastocyst Stage Embryo Affect the Chance of Having a Boy?
-
Jul 25, 2026, 10:33Rokaya Hachicho: The Hidden Cost of Excessive Laser Use During Trophectoderm Biopsy!
-
Jul 25, 2026, 10:31Join the ISUOG Webinar on Late-Evolving Fetal Anomalies – ISUOG
-
Jul 25, 2026, 10:29Waiting Before Clamping the Umbilical Cord Improves Neonatal Outcomes! – RCOG
-
Jul 25, 2026, 10:27Christopher Robinson: The Impact of Body Mass Index on Misoprostol Dosing for Labor Induction!
-
Jul 25, 2026, 10:26Heavy Menstrual Bleeding and Dysmenorrhea in Adolescents – IJGO